Literature DB >> 11139191

Defective neutrophil degranulation induced by interleukin-8 and complement 5a and down-regulation of associated receptors in children vertically infected with human immunodeficiency virus type 1.

S Meddows-Taylor1, L Kuhn, T M Meyers, G Sherman, C T Tiemessen.   

Abstract

The polymorphonuclear neutrophils (PMNs) of patients infected with human immunodeficiency virus type 1 (HIV-1) show impaired microbicidal responses. The present study assessed the functional integrity of PMN degranulation responses and the expression of specific receptors that mediate these responses in a group of children vertically infected with HIV-1. PMN degranulation in response to interleukin-8 (IL-8) and complement 5a (C5a) was measured in a group of HIV-1-infected children with mild and severe clinical disease and in an uninfected control group. In addition, the expression of CXCR1, CXCR2, and CD88 on whole-blood PMNs was quantified by flow cytometry. Although CXCR1 expression was found to be largely unaltered in the HIV-1-infected children relative to that in the control children, the intensity of CXCR2 expression was significantly reduced in those with severe disease. Furthermore, there was a significant reduction in the percentage of cells expressing CD88 and in the intensity of CD88 fluorescence in the HIV-1-infected children compared to that in control children, with CD88 fluorescence intensity more significantly reduced in the presence of severe disease. PMNs from a large proportion of the HIV-1-infected children either showed reciprocal degranulation responses or were unresponsive to IL-8 and C5a, whereas the PMNs from the uninfected children showed positive responses. Inefficient agonist-induced degranulation may contribute to the increased susceptibility of HIV-1-infected children to secondary microbial infections. Furthermore, reduced expression of CXCR2 and CD88 may be suggestive of defects in other functions of PMNs from HIV-1-infected children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11139191      PMCID: PMC96006          DOI: 10.1128/CDLI.8.1.21-30.2001

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  40 in total

1.  Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.

Authors:  J M Schröder; U Mrowietz; E Morita; E Christophers
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

Review 2.  Early biochemical events in leukocyte activation.

Authors:  R R Sandborg; J E Smolen
Journal:  Lab Invest       Date:  1988-09       Impact factor: 5.662

3.  Impairment of neutrophil bactericidal capacity in patients with AIDS.

Authors:  P M Murphy; H C Lane; A S Fauci; J I Gallin
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

4.  Intracellular control of human neutrophil secretion. II. Stimulus specificity of desensitization induced by six different soluble and particulate stimuli.

Authors:  P M Henson; N A Schwartzman; B Zanolari
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

5.  Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome.

Authors:  A Lazzarin; C Uberti Foppa; M Galli; A Mantovani; G Poli; F Franzetti; R Nóvati
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

6.  Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome.

Authors:  F H Valone; D G Payan; D I Abrams; E J Goetzl
Journal:  J Infect Dis       Date:  1984-08       Impact factor: 5.226

7.  Superoxide generation by human fetal granulocytes.

Authors:  P E Newburger
Journal:  Pediatr Res       Date:  1982-05       Impact factor: 3.756

8.  Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine.

Authors:  D C Anderson; B J Hughes; C W Smith
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

9.  Aggregation of leukocytes induced by the complement-derived peptides C3a and C5a and by three synthetic formyl-methionyl peptides.

Authors:  B Damerau; E Grünefeld; W Vogt
Journal:  Int Arch Allergy Appl Immunol       Date:  1980

10.  Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. Evidence that the same oxidase is activated by different transductional mechanisms.

Authors:  L C McPhail; R Snyderman
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

View more
  5 in total

1.  Altered expression of L-selectin (CD62L) on polymorphonuclear neutrophils of children vertically infected with human immunodeficiency virus type 1.

Authors:  S Meddows-Taylor; L Kuhn; T M Meyers; C T Tiemessen
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

2.  Critical role of the C5a-activated neutrophils in high-fat diet-induced vascular inflammation.

Authors:  Mizuko Osaka; Shunsuke Ito; Masaki Honda; Yukihiro Inomata; Kensuke Egashira; Masayuki Yoshida
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

3.  Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.

Authors:  Kerstin Pohl; David P Nichols; Jennifer L Taylor-Cousar; Milene T Saavedra; Matthew J Strand; Jerry A Nick; Preston E Bratcher
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

Review 4.  Orchestration of Neutrophil Extracellular Traps (Nets), a Unique Innate Immune Function during Chronic Obstructive Pulmonary Disease (COPD) Development.

Authors:  Anjali Trivedi; Meraj A Khan; Geetanjali Bade; Anjana Talwar
Journal:  Biomedicines       Date:  2021-01-08

5.  Effect of Antiretroviral Therapy on Neutrophil Oxidative Burst in Children.

Authors:  Nama Habib Ur Rehman; Pooja Dewan; Richa Gupta; Sunil Gomber; Alpana Raizada
Journal:  Indian J Pediatr       Date:  2022-08-10       Impact factor: 5.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.